Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$6.96
+6.1%
$6.67
$4.09
$17.24
$148.81M0.84302,775 shs111,434 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$4.77
+4.8%
$4.77
$3.51
$16.95
$41.21M0.24111,008 shs337,474 shs
NextCure, Inc. stock logo
NXTC
NextCure
$4.90
+3.4%
$0.47
$2.69
$21.84
$157.34M1.0614,788 shs62,405 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.34
-0.7%
$1.32
$1.21
$2.04
$1.06B1.344.03 million shs1.97 million shs
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
$18.03
$18.03
$5.31
$31.73
$1.42B2.323.17 million shsN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
0.00%-16.86%-12.53%+33.06%-59.00%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%-1.52%+3.64%+8.08%-67.85%
NextCure, Inc. stock logo
NXTC
NextCure
0.00%-9.61%-42.00%+26.60%-76.06%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%+0.37%+1.50%-4.93%-2.17%
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.9073 of 5 stars
3.41.00.04.72.72.50.0
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
4.0176 of 5 stars
3.50.00.04.62.92.50.6
NextCure, Inc. stock logo
NXTC
NextCure
3.2262 of 5 stars
1.33.00.04.33.51.70.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.0215 of 5 stars
3.50.00.04.42.33.30.6
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.80
Moderate Buy$18.00158.62% Upside
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.00
Buy$37.40684.07% Upside
NextCure, Inc. stock logo
NXTC
NextCure
2.67
Moderate Buy$3.50-28.57% Downside
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.75105.22% Upside
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ENTA, OPK, PTLA, NXTC, and KPTI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$27.00
7/8/2025
NextCure, Inc. stock logo
NXTC
NextCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/1/2025
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/3/2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$67.64M2.20N/AN/A$6.08 per share1.14
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$145.24M0.28N/AN/A($22.10) per share-0.22
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$2.34 per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.49$0.07 per share19.62$2.00 per share0.67
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
$116.64M12.13N/AN/A$1.67 per share10.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$76.42M-$13.26N/AN/AN/A-43.99%N/A-35.95%8/5/2025 (Estimated)
NextCure, Inc. stock logo
NXTC
NextCure
-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
-$290.66M-$4.06N/AN/AN/A-232.73%-267.86%-54.66%N/A

Latest ENTA, OPK, PTLA, NXTC, and KPTI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.39N/AN/AN/AN/AN/A
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
8/5/2025Q2 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$3.72N/AN/AN/A$37.92 millionN/A
8/4/2025Q3 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.10N/AN/AN/A$16.21 millionN/A
5/12/2025Q2 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million
5/12/2025Q1 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million
5/1/2025Q1 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.40-$0.39+$0.01-$0.39N/AN/A
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
5.29
5.29
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
1.33
1.28
NextCure, Inc. stock logo
NXTC
NextCure
N/A
10.26
10.26
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
4.77
4.87
4.82

Institutional Ownership

CompanyInstitutional Ownership
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
98.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16021.38 million18.41 millionOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3808.64 million8.40 millionOptionable
NextCure, Inc. stock logo
NXTC
NextCure
9032.11 million27.84 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
32478.48 millionN/AOptionable

Recent News About These Companies

Portola Middle
Fault lines in Portola Valley
Portola-Butler Continuation High School
Eagle Pharmaceuticals
Portola, CA 10-Day Weather Forecast
PTLA_old Historical Data
KPRX Kiora Pharmaceuticals, Inc.
Portola Music Festival
Portola Valley, CA Weather Conditions
Portola, CA Weather Conditions
Portola Pharma Investors Want Class Status for Securities Suit

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$6.96 +0.40 (+6.10%)
Closing price 04:00 PM Eastern
Extended Trading
$6.96 0.00 (0.00%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$4.77 +0.22 (+4.84%)
Closing price 04:00 PM Eastern
Extended Trading
$4.77 0.00 (0.00%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

NextCure stock logo

NextCure NASDAQ:NXTC

$4.90 +0.16 (+3.38%)
Closing price 04:00 PM Eastern
Extended Trading
$4.95 +0.05 (+1.02%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.34 -0.01 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 0.00 (0.00%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Portola Pharmaceuticals stock logo

Portola Pharmaceuticals NASDAQ:PTLA

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.